160 related articles for article (PubMed ID: 36107519)
21. Circulating melanoma cells as a potential biomarker to detect metastasis and evaluate prognosis.
Hida T; Yoneta A; Wakamatsu K; Yanagisawa K; Ishii-Osai Y; Kan Y; Kato J; Yamashita T
Australas J Dermatol; 2016 May; 57(2):145-9. PubMed ID: 26931184
[TBL] [Abstract][Full Text] [Related]
22. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression.
Hirai S; Kageshita T; Kimura T; Tsujisaki M; Imai K; Wakamatsu K; Ito S; Ono T
Melanoma Res; 1997 Feb; 7(1):58-62. PubMed ID: 9067966
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of serum 5-S-cysteinyl-dopa as a biomarker for predicting prognosis and detecting relapse in patients with advanced stage malignant melanoma.
Umemura H; Yamasaki O; Kaji T; Otsuka M; Asagoe K; Takata M; Iwatsuki K
J Dermatol; 2017 Apr; 44(4):449-454. PubMed ID: 27786364
[TBL] [Abstract][Full Text] [Related]
24. Use of serum 5-S-CD and S-100B protein levels to monitor the clinical course of malignant melanoma.
Bánfalvi T; Gilde K; Gergye M; Boldizsár M; Kremmer T; Ottó S
Eur J Cancer; 2003 Jan; 39(2):164-9. PubMed ID: 12509947
[TBL] [Abstract][Full Text] [Related]
25. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.
Sasaki Y; Shimizu H; Naka W; Takeshita E; Nishikawa T
Acta Derm Venereol; 1997 Sep; 77(5):379-81. PubMed ID: 9298132
[TBL] [Abstract][Full Text] [Related]
27. Treatment of primary melanoma of the lung monitored by 5-S-cysteinyldopa levels.
Shikuma K; Omasa M; Yutaka Y; Okuda M; Taki T
Ann Thorac Surg; 2009 Apr; 87(4):1264-6. PubMed ID: 19324166
[TBL] [Abstract][Full Text] [Related]
28. 5-S-cysteinyldopa as diagnostic tumor marker for uveal malignant melanoma.
Goto H; Usui M; Wakamatsu K; Ito S
Jpn J Ophthalmol; 2001; 45(5):538-42. PubMed ID: 11583680
[TBL] [Abstract][Full Text] [Related]
29. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
Paul E; Graef V; Ruppel R
Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
[TBL] [Abstract][Full Text] [Related]
30. Studies on amelanotic melanoma with the fluorescence method (Falck and Hillarp) and biochemical analysis of 5-S-cysteinyldopa in the tissues.
Morishima T; Tatsumi F; Fukada E; Watanabe M; Nagashima N; Hanawa S
Arch Dermatol Res; 1983; 275(5):329-33. PubMed ID: 6419680
[TBL] [Abstract][Full Text] [Related]
31. [Excretion of 5-S-cysteinyldopa in the urine of Japanese patients with malignant melanoma--a helpful biochemical marker for assessing the progression of disease].
Hanawa S
Nihon Hifuka Gakkai Zasshi; 1983 Mar; 93(4):433-42. PubMed ID: 6411952
[No Abstract] [Full Text] [Related]
32. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
33. Measurement of eumelanin precursor metabolites in the urine as a new marker for melanoma metastases.
Yamada K; Walsh N; Hara H; Jimbow K; Chen H; Ito S
Arch Dermatol; 1992 Apr; 128(4):491-4. PubMed ID: 1580656
[TBL] [Abstract][Full Text] [Related]
34. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
[TBL] [Abstract][Full Text] [Related]
35. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction--high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma.
Hartleb J; Damm Y; Arndt R; Christophers E; Stockfleth E
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):31-42. PubMed ID: 10360420
[TBL] [Abstract][Full Text] [Related]
36. Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese.
Wakamatsu K; Ito S
Pigment Cell Res; 1995 Jun; 8(3):132-4. PubMed ID: 7567788
[TBL] [Abstract][Full Text] [Related]
37. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma.
Kärnell R; Kågedal B; Lindholm C; Nilsson B; Arstrand K; Ringborg U
Melanoma Res; 2000 Aug; 10(4):363-9. PubMed ID: 10985671
[TBL] [Abstract][Full Text] [Related]
38. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
[TBL] [Abstract][Full Text] [Related]
39. [5-S-cysteinyldopa determination in the urine. Its value for monitoring in melanoma patients].
Paul E; Graef V; Ruppel R; Hellwich M
Z Hautkr; 1983 Feb; 58(4):262-5. PubMed ID: 6405551
[TBL] [Abstract][Full Text] [Related]
40. Pedunculated pigmented eccrine poroma of the scalp with increased urinary excretion of 5-S-cysteinyldopa.
Jin KM; Nogita T; Toyoda H; Kawashima M; Hidano A
J Dermatol; 1990 Sep; 17(9):555-8. PubMed ID: 2177483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
